Jantoven Shortage: What Providers and Prescribers Need to Know in 2026

Jantoven (warfarin sodium, Upsher-Smith Laboratories) is one of the most prescribed anticoagulants in the United States, with millions of patients dependent on it for management of atrial fibrillation, venous thromboembolism, mechanical heart valves, and other thromboembolic conditions. While no formal FDA shortage has been declared for Jantoven or generic warfarin as of 2026, clinicians are increasingly fielding patient calls about difficulty locating the brand. This guide provides clinically relevant information for prescribers, anticoagulation clinic staff, and advanced practice providers.

Current Jantoven Supply Status (2026)

As of this writing, Jantoven is not listed on the FDA Drug Shortage Database. Generic warfarin is produced by multiple domestic and international manufacturers, providing supply chain redundancy. The primary access barrier patients face is not a supply disruption but rather routine pharmacy stocking practices: most pharmacies stock generic warfarin exclusively and do not carry the Jantoven brand.

For patients on a brand-specific prescription, this creates a functional access barrier. Proactive prescriber guidance can prevent dangerous therapy gaps.

Clinical Considerations When Patients Can't Obtain Jantoven

Warfarin's narrow therapeutic index (NTI) designation by the FDA means that even minor pharmacokinetic differences between formulations can result in clinically meaningful INR fluctuations. The FDA requires NTI drug generics to meet tighter bioequivalence standards (within 90% confidence intervals of 90.00–111.11% for AUC and Cmax), providing a theoretical basis for therapeutic equivalence.

However, real-world clinical experience and some published literature suggest that a subset of patients — particularly those with highly variable INRs or those on complex polypharmacy regimens — may experience INR shifts when formulations change. This does not mean transitions should be avoided, but they require active management.

Protocol for Brand-to-Generic Warfarin Transitions

When transitioning a patient from Jantoven to generic warfarin (or between generic manufacturers), the following approach is recommended:

Maintain the same milligram dose — do not adjust empirically at the time of switch.

Obtain an INR within 7 to 14 days of the transition to confirm therapeutic range is maintained.

Educate the patient that the pill color and appearance will change — this is expected and does not indicate a problem.

Document the formulation change in the medical record and flag for the anticoagulation team if applicable.

If the patient experiences unexplained INR variability after transition, consider reverting to the brand or stabilizing on a consistent generic manufacturer.

When to Consider DOAC Therapy Instead

Persistent brand availability barriers may provide an opportunity to reconsider anticoagulant therapy choice for appropriate patients. Current ACC/AHA and ASH guidelines favor DOACs over warfarin for most patients with non-valvular atrial fibrillation and venous thromboembolism, citing lower rates of intracranial hemorrhage and simpler dosing. Consider DOAC therapy if the patient:

Has non-valvular AFib and no contraindications to DOACs (adequate renal function, no drug interactions)

Has DVT/PE without antiphospholipid syndrome (particularly triple-positive APLS, where warfarin is preferred)

Has had poor INR control on warfarin (time in therapeutic range <65%)

Has difficulty adhering to dietary restrictions or frequent monitoring visits

Absolute contraindications to DOACs: Mechanical heart valves, moderate-to-severe mitral stenosis, and pregnancy. These patients must remain on warfarin.

DOAC Options and Key Differentiators

Apixaban (Eliquis): Lowest major bleeding risk in comparative studies; twice-daily dosing; minimal renal elimination (27%); approved for AFib, DVT/PE; generic now available.

Rivaroxaban (Xarelto): Once-daily with evening meal; generic available; higher GI bleeding vs. apixaban; approved for AFib, DVT/PE, and secondary CAD/PAD prevention.

Dabigatran (Pradaxa): Direct thrombin inhibitor; 80% renally eliminated — avoid if CrCl <15 mL/min; higher GI adverse effects; idarucizumab reversal agent available; generic available.

Edoxaban (Savaysa): Once-daily; avoid if CrCl >95 mL/min (reduced efficacy in AFib); requires parenteral anticoagulation bridge before initiation.

Communicating with Patients About Availability Issues

When patients contact your office about difficulty finding Jantoven, a structured approach can reduce anxiety and prevent therapy gaps. Recommended talking points:

Reassure the patient there is no national Jantoven shortage; the issue is local pharmacy stocking.

Instruct them to use medfinder.com to locate pharmacies near them with Jantoven in stock.

Authorize a temporary generic substitution if the brand truly cannot be found, and schedule a follow-up INR in 1-2 weeks.

Document all formulation changes in the medication record.

Resources for Providers

FDA Drug Shortage Database: fda.gov/drugs/drug-safety-and-availability/drug-shortages

ASHP Drug Shortage Resource Center: ashp.org/drug-shortages

ACC/AHA Anticoagulation Guidelines (2023 update)

To help your patients find Jantoven or any warfarin formulation near them, direct them to medfinder for providers — a service that calls pharmacies on behalf of patients to confirm stock availability.

For a complete provider workflow, see our guide on how to help your patients find Jantoven in stock.